RxDoctor Payments Data

Ivan Coronado, MD

Internal Medicine · Delray Beach, FLNPI 1790705721

Payments from drug & device makers

$14,180in general payments, 2019–2025

Across 260 payments — averaging $54.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Boston Scientific$2K
  • Atricure, Inc.$2K
  • Medtronic$1K
  • AstraZeneca$907
  • Pfizer$723
  • plus $5K from 36 others

What the payments were for

  • Travel & lodging$1,1028%
  • Food & beverage$12,87291%
  • Education$2061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,180 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$690,893
Medicare patients
1,461
Services billed
5,243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban207$273,996
XareltoRivaroxaban51$67,709
MultaqDronedarone Hcl18$26,594
EntrestoSacubitril/Valsartan26$23,980
Metoprolol Succinate204$3,725
Rosuvastatin Calcium238$3,484
Olmesartan Medoxomil104$2,119
Ezetimibe80$2,022
Flecainide Acetate25$1,848
Losartan Potassium128$1,785
Ranolazine ErRanolazine29$1,745
Amlodipine Besylate204$1,477
Valsartan37$1,273
Atorvastatin Calcium104$1,168
Amiodarone Hcl45$779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$723$273,996207 claims
Johnson & JohnsonXarelto$269$67,70951 claims
Sanofi-aventis U.S. LLCMultaq$23$26,59418 claims
NovartisEntresto$229$23,98026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →